Prescription medicine
Latanoprostene bunod Brand names: Vyzulta
Latanoprostene bunod (Vyzulta) is a prescription medicine with an FDA approval on record since 2017. A generic is approved and listed by 1 labeler, but in the October 7, 2026 NADAC survey pharmacies bought only the brand, at $102.27 per mL (Vyzulta 0.024% eye solution).
- Generic approved
Check it at the source: the latanoprostene bunod FDA label on DailyMed (effective February 27, 2024, Bausch & Lomb Incorporated); the NDA 207795 record on Drugs@FDA; every latanoprostene bunod label on DailyMed.
Highlights of the record
FDA label of February 27, 2024; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageVYZULTA ® (latanoprostene bunod ophthalmic solution) 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Forms and strengths
- 0.24 mg/ml
Solution/ drops.
On the market
- Earliest approval on file
- November 2, 2017 Vyzulta, Bausch And Lomb; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 1 first April 29, 2025; 1 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 2 of which 1 under generic applications, 1 under brand applications, repackagers included
- Last listed patent
- February 21, 2029 Vyzulta solution/drops; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $102.27 per mL Vyzulta 0.024% eye solution
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 1,071 through July 30, 2026
What is latanoprostene bunod used for?
From the label: indications and usageVYZULTA ® (latanoprostene bunod ophthalmic solution) 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. VYZULTA is a prostaglandin analog indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Conditions named in the indications of latanoprostene bunod's FDA labels, with every medicine labeled for each:
Source: FDA drug label (Vyzulta), Bausch & Lomb Incorporated, effective February 27, 2024 (SPL set 60ce7900-a677-4fc2-88d0-1603baa9dbd4), via openFDA; the full label on DailyMed
Is there a generic for latanoprostene bunod (Vyzulta)?
The FDA approved the first generic latanoprostene bunod on April 29, 2025. 1 generic application is approved; 1 of it carries a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists latanoprostene bunod from 1 labeler under a generic (ANDA) application and from 1 brand labeler. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it. In the latest NADAC survey pharmacies bought only the brand, so a generic may not be on sale yet.
The Orange Book lists 1 patent for Vyzulta solution/drops: the compound patent runs to February 21, 2029. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2017 earliest approval on file
- 2025 first generic approved
- 2029 last listed patent
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for latanoprostene bunod (Vyzulta)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $102.27 per mL (Vyzulta 0.024% eye solution), up 3% from $99.42 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Vyzulta 0.024% eye solution (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Vyzulta 0.024% eye solution | Brand | $102.27 per mL | n/a | +3% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What does the latanoprostene bunod label say about other medicines?
The latanoprostene bunod label names 1 other medicine in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Benzalkonium | warnings and precautions | Contact lenses should be removed prior to the administration of VYZULTA because this product contains benzalkonium chloride. |
Source: FDA drug label (Vyzulta), Bausch & Lomb Incorporated, effective February 27, 2024 (SPL set 60ce7900-a677-4fc2-88d0-1603baa9dbd4), via openFDA; the full label on DailyMed
What do FAERS reports show for latanoprostene bunod?
The FDA Adverse Event Reporting System holds 1,071 reports that list latanoprostene bunod among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 51 are coded as a death and 107 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as latanoprostene bunod?
17 other medicines are given the same way (ophthalmic) and in the same FDA class as latanoprostene bunod or labeled mainly for the same use (glaucoma), the same class first. Glaucoma lists all 20 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (ophthalmic) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Timolol | Glaucoma | 21 labelers | $0.774 per mL 0.5% eye drops | No current entry |
| Brimonidine | Glaucoma | 12 labelers | $9.06 per mL 0.1% drop | No current entry |
| Bimatoprost | Glaucoma | 13 labelers | $6.97 per mL 0.03% eye drops | No current entry |
| Dorzolamide and timolol | Glaucoma | 14 labelers | $0.893 per mL Dorzolamide-timolol eye drops | No current entry |
| Brimonidine and timolol | Glaucoma | 14 labelers | $2.15 per mL 0.2%-0.5% | No current entry |
| Latanoprost | Glaucoma | 14 labelers | $1.58 per mL 0.005% eye drops | No current entry |
| Travoprost | Glaucoma | 11 labelers | $9.07 per mL 0.004% eye drop | A presentation being discontinued |
| Dorzolamide | Glaucoma | 14 labelers | $0.835 per mL 2% eye drops | No current entry |
Every medicine labeled for the same conditions as latanoprostene bunod
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Alternatives to latanoprostene bunod
- 17 medicines for the same use
- Latanoprostene bunod side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other